Korneuburg, Austria, July 22nd, 2026 – Marinomed Biotech AG (VSE:MARI) announces the
filing of a court restructuring proceeding without self-administration as announced on July
16th.
Marinomed further announces that the existing contract for the provision of liquidity services
(market making) with Raiffeisen Bank International has been terminated by the contractual
partner with immediate effect. Due to the sudden cessation of market making, there may
be a short-term decrease in liquidity for trading Marinomed Biotech AG shares and larger
bid-ask spreads. The tradability of the shares on the respective stock exchanges remains
fundamentally unaffected. The Management Board is working to agree on a successor
market-making mandate promptly and to restore the usual liquidity in the trading of the
shares.
Due to the current developments, Marinomed Biotech AG is postponing the publication of
its 2026 half-year financial report, which was originally scheduled for September 16, 2026.
+++ End of ad-hoc announcement +++